Key facts
- Notable investors include Plug and Play Tech Center, Stanford University, California Life Sciences, First In Ventures, Forcefield Venture — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Acrobat Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Acrobat Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Acrobat Genomics
Developer of a drug discovery platform designed to offer deliverable and controllable gene editing tools. The company utilizes computationally-guided screening to rapidly develop these tools for both therapeutic and defense applications.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2022
- Employees
- 4
- Website
- acrobatgenomics.com/
- Ownership
- Privately Held (backing)
Acrobat Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Acrobat Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Acrobat Genomics in its N-PORT filings yet. We sweep new filings monthly.